Becton, Dickinson and Company: Tariff Fluctuations, Possible Organic Growth Struggles & Challenges That Lie Ahead!

Becton, Dickinson and Company (BD) recently reported its second fiscal quarter 2025 results, which reflect both achievements and challenges impacting its financial performance and strategic outlook. Notably, the company’s revenue fell below expectations, growing 6% year-over-year or 0.9% organically. This shortfall was attributed mainly to dynamics within the Life Sciences segment, particularly due to reduced global research funding and slower-than-anticipated normalization in diagnostics testing. These factors prompted BD to adjust its full-year organic growth guidance to 3-3.5%, down from initial estimates.